Ermaris Bio

Executive Summary

Ermaris Bio is a private, preclinical-stage biotechnology company headquartered in Cambridge, Massachusetts, founded in 2021. The company is dedicated to discovering and developing novel small molecule therapeutics for serious diseases, with initial focus areas spanning oncology, immunology, ophthalmology, and cardiovascular indications. Operating in a capital-efficient manner, Ermaris aims to identify promising preclinical candidates and advance them through early clinical development, leveraging internal expertise and potential partnerships. As a young entity with no disclosed financing rounds or public pipelines, the company remains in a stealth-like phase, positioning itself for future value creation through its diverse therapeutic scope and small molecule platform.

Upcoming Catalysts (preview)

• Q4 2026Publication of Lead Program Preclinical Data60% success
• Q2 2027Series A Financing Announcement50% success
• Q4 2027IND Filing for Lead Asset30% success